Advertisement

Replacement Hormone Therapy for Gender Dysphoria and Congenital Sexual Anomalies

Chapter
  • 350 Downloads
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1242)

Abstract

What is it about sexuality that makes it such a burning matter since the dawn of mankind? Much was lost of humankind heritage because of society’s attitude toward sex and gender, but we’ve made progress. Medical knowledge progressed incredibly and so did social and cultural norms. In these days, on most places on the planet, there is acceptance. Still, gender issues take a center stage, often inflaming the social and political milieu everywhere. So how informed and prepared is the medical community to deal with these issues? Aside from medical treatments, gender dysphoric patients need mental health and social support throughout life. Do we have enough guidelines for treatments that have life-long effects? Do we actually know all of those effects? There are many issues to consider, like fertility preservation, puberty suppression with its adverse effects, and not in the least, the effects of the hormonal therapy on the target tissues.

Keywords

Gender dysphoria Congenital sexual anomalies Hormone therapy Replacement hormones Estrogen Progesterone 

References

  1. 1.
    Martine Rothblatt. The apartheid of sex.Google Scholar
  2. 2.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013. p. 451–9.CrossRefGoogle Scholar
  3. 3.
    Frisén L, Söder O, Rydelius PA. Dramatic increase of gender dysphoria in youth. Läkartidningen. 2017.Google Scholar
  4. 4.
    Cartaya J, Lopez X. Gender dysphoria in youth: a review of recent literature. Curr Opin Endocrinol Diabetes Obes. 2018;25(1):44–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Aitken M, Steensma TD, Blanchard R, et al. Evidence for an altered sex ratio in clinic-referred adolescents with gender dysphoria. J Sex Med. 2015;12:756–63.PubMedCrossRefGoogle Scholar
  6. 6.
    Streed CG Jr, McCarthy EP, Haas JS. Association between gender minority status and self-reported physical and mental health in the United States. JAMA Intern Med. 2017;177:1210–2.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Klein DA, Paradise SL, Goodwin ET. Caring for transgender and gender-diverse persons: what clinicians should know. Am Fam Physician. 2018;98(11):645–53.PubMedGoogle Scholar
  8. 8.
    WPATH. Clarification on medical necessity of treatment, sex reassignment, and insurance coverage for transgender and transsexual people worldwide [Internet]. http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1352&pk_association_webpage=3947
  9. 9.
    Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2012;13(4):165–232.CrossRefGoogle Scholar
  10. 10.
    Joint R, Chen ZE, Cameron S. Breast and reproductive cancers in the transgender population: a systematic review [published online ahead of print April 28, 2018]. BJOG. 2018;125:1505.  https://doi.org/10.1111/1471-0528.15258.PubMedCrossRefGoogle Scholar
  11. 11.
    Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017;102(11):3914–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, et al. Effect of sex steroids on the bone health of transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017;102(11):3904–13.PubMedCrossRefGoogle Scholar
  13. 13.
    Meriggiola MC, Gava G. Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen. Clin Endocrinol. 2015;83(5):597–606.CrossRefGoogle Scholar
  14. 14.
    Weinand JD, Safer JD. Hormone therapy in transgender adults is safe with provider supervision; a review of hormone therapy sequelae for transgender individuals. J Clin Transl Endocrinol. 2015;2(2):55–60.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Deutsch MB. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. 2nd ed. 2016. http://transhealth.ucsf.edu/protocols. Accessed 5 July 2018.
  16. 16.
    Endocrine Society Updates Guidelines on Transgender Medical Care. Veronica Hackenthal. 2017. www.medscape.com
  17. 17.
    Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine. Society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2018;103(2):699]. J Clin Endocrinol Metab. 2017;102(11):3869–903.PubMedCrossRefGoogle Scholar
  18. 18.
    Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88(8):3467–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat. 2015;149(1):191–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Gooren L, Morgentaler A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia. 2014;46(10):1156–60.PubMedCrossRefGoogle Scholar
  21. 21.
    Turo R, Jallad S, Prescott S, Cross WR. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can Urol Assoc J. 2013;7(7–8):E544–6.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Spratt DI, Stewart II, Savage C, et al. Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients. J Clin Endocrinol Metab. 2017;102:2349–55.PubMedCrossRefGoogle Scholar
  23. 23.
    Costa LBF, Rosa-E-Silva ACJS, Medeiros SF, Nacul AP, Carvalho BR, Benetti-Pinto CL, Yela DA, Maciel GAR, Soares Júnior JM, Maranhão TMO. Recommendations for the use of testosterone in male transgender. Rev Bras Ginecol Obstet. 2018;40(5):275–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012;9(10):2641–51.PubMedCrossRefGoogle Scholar
  25. 25.
    Urban RR, Teng NNH, Kapp DS. Gynecologic malignancies in female-to-male transgender patients: the need of original gender surveillance. Am J Obstet Gynecol. 2011;204(5):e9–12.PubMedCrossRefGoogle Scholar
  26. 26.
    Grynberg M, Fanchin R, Dubost G, Colau J-C, Brémont-Weil C, Frydman R, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online. 2010;20(4):553–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, et al. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med. 2009;6(11):3193–200.PubMedCrossRefGoogle Scholar
  28. 28.
    Dizon DS, Tejada-Berges T, Koelliker S, Steinhoff M, Granai CO. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Investig. 2006;62(4):226–8.CrossRefGoogle Scholar
  29. 29.
    Hage JJ, Dekker JJ, Karim RB, Verheijen RH, Bloemena E. Ovarian cancer in female-to-male transsexuals: report of two cases. Gynecol Oncol. 2000;76(3):413–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Futterweit W, Deligdisch L. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab. 1986;62(1):16–21.PubMedCrossRefGoogle Scholar
  31. 31.
    Futterweit W, Deligdisch L. Effects of androgens on the ovary. Fertil Steril. 1986;46(2):343–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol. 2013;169(4):471–8.PubMedCrossRefGoogle Scholar
  33. 33.
    American Fertility Society. The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, Müllerian anomalies and intrauterine adhesions. Fertil Steril. 1988;49:944–55.CrossRefGoogle Scholar
  34. 34.
    Chandler TM, Machan LS, Cooperberg PL, Harris AC, Chang SD. Müllerian duct anomalies: from diagnosis to intervention. Pictorial review. Brit J Radiol. 2009;82:1034–42.PubMedCrossRefGoogle Scholar
  35. 35.
    Grimbizis GF, Campo R, Gordts S, Brucker S, Gergolet M, Tanos V, et al. Clinical approach for the classification of congenital uterine malformations. Gynecol Surg. 2012;9:119–29.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Grimbizis GF, Gordts S, Spiezio Sardo A, Brucker S, De Angelis C, Gergolet M, et al. The ESHRE/ESGE consensus on the classification of female genital tract congenital anomalies. Hum Reprod. 2013;28:2032–44.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Acién P, Acién M. Diagnostic imaging and cataloguing of female genital malformations. Insights Imaging. 2016;7(5):713–26.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Witchel SF. Disorders of sex development. Best Pract Res Clin Obstet Gynaecol. 2018;48:90–102.PubMedCrossRefGoogle Scholar
  39. 39.
    Lee PA, Nordenström A, Houk CP, et al. Global disorders of sex development update since 2006: perceptions, approach and care. Horm Res Paediatr. 2016;85:158–80.PubMedCrossRefGoogle Scholar
  40. 40.
    Hughes IA, Nihoul-Fékété C, Thomas B, et al. Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development. Best Pract Res Clin Endocrinol Metab. 2007;21:351–65.PubMedCrossRefGoogle Scholar
  41. 41.
    Chen MJ, McCann-Crosby B, Gunn S, et al. Fluidity models in ancient Greece and current practices of sex assignment. Semin Perinatol. 2017;41:206–13.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Patel V, Casey RK, Gomez-Lobo V. Timing of gonadectomy in patients with complete androgen insensitivity syndrome-current recommendations and future directions. J Pediatr Adolesc Gynecol. 2016;29:320–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Laurian L, Finkelstein JO, Soferman N, Loewenthal M, Deligdisch L. Testicular feminization syndrome. Isr J Med Sci. 1971;7(5):668–73.PubMedGoogle Scholar
  44. 44.
    Becker D, Wain LM, Chong YH, Gosai SJ, Henderson NK, Milburn J, Stott V, Wheeler BJ. Topical dihydrotestosterone to treat micropenis secondary to partial androgen insensitivity syndrome (PAIS) before, during, and after puberty—a case series. J Pediatr Endocrinol Metab. 2016;29(2):173–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Altchek A, Deligdisch L. Pediatric adolescent and young adult gynecology: Blackwell Publishing; 2009.Google Scholar
  46. 46.
    Brännström M, Johannesson L, Bokström H, et al. Livebirth after uterus transplantation. Lancet. 2015;385:607–16.PubMedCrossRefGoogle Scholar
  47. 47.
    Testa G, McKenna GJ, Gunby RT Jr, et al. First live birth after uterus transplantation in the United States. Am Transplant. 2018;18:1270–4.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.New York Medical College, Westchester Medical CenterValhallaUSA

Personalised recommendations